Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EMC$33.86-0.28(-0.82%)EMC Insurance Receives Insurity's Excellence in Operational Efficiency Award[12:01:00 PM ET]SWMR$9.07+0.55(+6.51%)Swarmer to Host Investor Call to Discuss Acquisition of Ratel Robotics[12:00:00 PM ET]CMCSA$22.09-0.61(-2.67%)Comcast Completes Construction in Tulare County, Connecting Thousands to High-Speed Internet for the First Time[12:00:00 PM ET]GCDT$0.14-0.04(-21.86%)Green Circle Decarbonize Technology Limited Issues Statement Regarding Unusual Market Activity[11:45:00 AM ET]KLAR$12.62-0.19(-1.48%)Klarna's flexible payment options now available at Adorama, giving creators more ways to fuel their next project Adorama, a leading photography, video, audio, drone, and computer retailer, and Klarna, the everyday finance network, today announced that Klarna is...[11:39:00 AM ET]DUK$124.55-0.43(-0.34%)Duke Energy Florida shares tips for warding off energy vampires, saving money This Halloween, Duke Energy Florida is reminding customers of the scary reality of energy "vampires" – appliances and electronics lurking throughout...[11:39:00 AM ET]FFR$1.08-0.05(-4.87%)FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform FF EAI Robotics Ecosystem Inc. ("FFR") (NASDAQ: FFR), a U.S.-based Embodied AI robotics company, and Faraday Future Intelligent Electric Inc....[11:30:00 AM ET]MRK$141.85-3.42(-2.35%)Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer[11:30:00 AM ET]FFR$1.08-0.05(-4.87%)Faraday Future Announces Completion of FF EAI Robotics Ecosystem's (FFR) Acquisition of Faraday Future's Robotics Business and Establishment of a Nasdaq-Listed Humanoid and Bionic Robotics Platform[11:30:00 AM ET]STGW$8.66-0.33(-3.62%)Stagwell (STGW) Acquires Freestar, Leading Publisher Advertising Services Company[11:30:00 AM ET]PGNY$28.40-0.57(-1.97%)New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model[11:25:22 AM ET]

AUPH · NASDAQ

Aurinia Pharmaceuticals Inc.

$17.04 +0.18 (+1.07%)

Company overview

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical needs in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis and has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia is headquartered in Victoria, Canada.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.3B
Employees
130
Headquarters
Edmonton, BC
Website
auriniapharma.com
CEO
Kevin C. Tang
Listed
September 3, 2014
P/E
7.61
Dividend yield
0.00%

Company financials

Revenue
$298M
Gross profit
$268M
Operating income
$124M
EBITDA
$162M
Net income
$298M
EPS
$2.24
Total assets
$724M
Total debt
$68.6M
Gross margin
89.74%
Net margin
99.97%
Earnings yield
13.15%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

14.1715.4916.8118.1319.45
AUPH 1D NASDAQ O17.27H17.31L16.81C16.86-0.47 (-2.71%)Vol649.24K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Type
Ticker Type Headline Source Published
AUPHAurinia Pharmaceuticals Inc. Stock news Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term Zacks Investment Research
AUPHAurinia Pharmaceuticals Inc. Stock news Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term Zacks Investment Research
AUPHAurinia Pharmaceuticals Inc. Stock news Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL) Defense World
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises Zacks Investment Research
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug Benzinga
AUPHAurinia Pharmaceuticals Inc. Press release Aurinia Settles Patent Litigation with Teva Business Wire
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals Doubles Down On Its Pipeline Seeking Alpha
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates Zacks Investment Research
AUPHAurinia Pharmaceuticals Inc. Press release Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress Business Wire
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis GuruFocus
AUPHAurinia Pharmaceuticals Inc. Press release Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis Business Wire
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow Seeking Alpha
AUPHAurinia Pharmaceuticals Inc. Press release LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death Business Wire
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript Seeking Alpha
AUPHAurinia Pharmaceuticals Inc. Press release Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences Newsfile Corp
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates Zacks Investment Research
AUPHAurinia Pharmaceuticals Inc. Press release Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress Business Wire
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison Defense World
AUPHAurinia Pharmaceuticals Inc. Stock news Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts Defense World
AUPHAurinia Pharmaceuticals Inc. Stock news SG Americas Securities LLC Grows Position in Aurinia Pharmaceuticals Inc $AUPH Defense World
See more
FAQ

Questions about Aurinia Pharmaceuticals Inc.

What does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical needs in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis and has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia is headquartered in Victoria, Canada.
What is AUPH's market cap?
Aurinia Pharmaceuticals Inc. (AUPH) is a listed stock with a live quote. The latest market cap on this page is $2.3B.
Where is Aurinia Pharmaceuticals Inc. headquartered?
Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, BC.
How do I get AUPH news from the API?
Call GET /v1/news?tickers=AUPH. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does AUPH news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AUPH, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the AUPH price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs